The Economist7h
Designing babies
â–  ...
Travere Therapeutics, Inc.: Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Company to submit sNDA around the end of 1Q 2025 seeking traditional approval of FILSPARI® (sparsentan) for FSGS Net product sales of FILSPARI totaled $50 million in 4Q 2024; $132 million for full yea ...
eLife2d
SMARCAD1 and TOPBP1 contribute to heterochromatin maintenance at the transition from the 2C-like to the pluripotent state
The chromatin-bound proteome of embryonic stem cells transitioning to 2C-like cells uncovers chromatin regulators involved in heterochromatin formation.
finanzen2d
EQS-News: Mpox Clade 1 in the U.S. Highlights the Need for Vaccine Supply Diversification
EQS-News: GeoVax, Inc. / Key word (s): Financial Mpox Clade 1 in the U.S. Highlights the Need for Vaccine Supply Diversification 19.02.2025 / 15:04 CET/CEST The issuer is solely responsible for the ...